- Center on Health Equity & Access
- Clinical
- Health Care Cost
- Health Care Delivery
- Insurance
- Policy
- Technology
- Value-Based Care
Concluding Thoughts on the Future of CSCC and BCC Care
The panel provides closing thoughts on the future of the CSCC and BCC treatment landscape.
EP: 1.Prevalence of Cutaneous Squamous Cell Carcinoma (CSCC) & Basal Cell Carcinoma (BCC)
EP: 2.Immunotherapy Landscape in cSCC and BCC
EP: 3.Immunotherapy and Radiation Therapy in cSCC and BCC
EP: 4.Immunotherapy Barriers: Multidisciplinary Approach in cSCC and BCC
EP: 5.Coordination of Care: Interdisciplinary Immunotherapy Challenges in Nonmelanoma Skin Cancers
EP: 6.Multidisciplinary Collaboration: Best Practices for CSCC and BCC Management
EP: 7.Dermatologists and Immunotherapy: Managing Patient Expectations
EP: 8.Monitoring Immunotherapy Toxicities in CSCC and BCC
EP: 9.Staging Disease and Risk Stratification in CSCC and BCC
EP: 10.Targeted Therapy: Hedgehog Inhibitors in BCC
EP: 11.Socioeconomic Implications of CSCC and BCC
EP: 12.Immunosuppression in CSCC and BCC Treatment
EP: 13.Updates in Therapeutics for Nonmelanoma Skin Cancers
EP: 14.Concluding Thoughts on the Future of CSCC and BCC Care
This is a video synopsis/summary of a Peer Exchange involving Jason Luke, MD, FACP; Christopher Barker, MD; Omid Hamid, MD; Vishal Patel, MD; and Catherine Pisano, MD.
In concluding statements, Hamid reflected on tremendous progress from an era when advanced skin cancers were untreatable compared to the current landscape of effective immunotherapies and coordinated multidisciplinary care. He stressed ensuring patients understand available therapies and the ability to positively impact their disease. Pisano emphasized reclassifying basal cell and squamous cell carcinomas as serious vs indolent malignancies warranting immunotherapy when appropriate. She highlighted setting patient expectations and fully leveraging specialist expertise via integrated care teams. Barker advocated conducting pivotal trials through cooperative groups to refine care pathways, enable treatment de-escalation when feasible, and disseminate emerging strategies into community settings. Patel described the transformation of skin cancer conferences into multidisciplinary forums where cross-pollination of specialty knowledge ultimately optimizes patient-centered decision-making.
Video synopsis is AI-generated and reviewed by AJMC® editorial staff.
How FcRn Blockade Targets Myasthenia Gravis Autoantibodies
January 29th 2025In part 2 of our interview with Katie Abouzahr, MD, Johnson & Johnson Innovative Medicine, we discuss the challenge inherent in treating adolescents who have the myasthenia gravis and how nipocalimab works via FcRn blockade to reduce the circulating autoantibodies that drive myasthenia gravis.
Read More
Niraparib Extends PFS, Time to Next Treatment in Patients With EOC, Especially BRCA-Mutated Cases
January 28th 2025First-line maintenance (1LM) niraparib significantly extends progression-free survival (rwPFS) and time to next treatment (rwTTNT) in patients with epithelial ovarian cancer (EOC), with the greatest benefit observed in those considered homologous recombination-deficient (HRd) and those with BRCA-mutated (BRCAm) tumors.
Read More
